Safusidenib achieved a 51.9% response rate and 79.1% 36-month progression-free survival in grade 2 IDH1-mutant glioma, supporting new Phase 3 and Phase 2 studies.
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Nuvation Bio has reported updated long-term results from the Phase 2 J201 study (NCT04458272) showing durable clinical activity of its investigational IDH1 inhibitor, safusidenib, in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma. The findings, based on a median follow-up of 38.8 months, were accompanied by the launch of two new studies intended to broaden the drug’s development across different stages of IDH1-mutant glioma.
Durable Clinical Benefit with Extended Follow-up
Safusidenib is an oral, brain-penetrant, selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1), a genetic alteration found in the majority of IDH-mutant gliomas. By selectively blocking the mutant enzyme, the therapy aims to slow tumor growth while delaying the need for radiation or chemotherapy.
The updated Phase 2 J201 study included 27 patients in Japan with newly diagnosed grade 2 IDH1-mutant glioma who had not received chemotherapy or radiotherapy.
With nearly 40 months of follow-up, the centrally assessed confirmed objective response rate (ORR), based on Response Assessment in Neuro-Oncology (RANO) criteria for low-grade gliomas, reached 51.9%. Median progression-free survival (PFS) was not reached, while the estimated 36-month PFS rate was 79.1%.
Responses also remained durable over time. Only one patient who had previously responded experienced subsequent disease progression during follow-up. Investigators reported no new safety signals, with the overall safety profile remaining consistent and manageable.
New Phase 3 and Phase 2 Studies Expand Development Program
The updated efficacy data have supported a broader clinical development strategy for safusidenib.
The newly initiated G307 Phase 3 trial (NCT07712757) will enroll approximately 140 patients with newly diagnosed grade 2 IDH1-mutant glioma who have not yet received chemotherapy or radiation. The randomized, placebo-controlled study will be conducted outside the United States in regions where vorasidenib is not yet approved or widely available. Progression-free survival assessed by blinded independent central review will serve as the primary endpoint, alongside secondary measures including objective response rate, duration of response, time to response, and time to next intervention.
The company is also launching the G209 Phase 2 study (NCT07703436) in the United States. The multicenter trial will enroll up to 40 patients with grade 2 or grade 3 IDH1-mutant glioma whose disease has progressed following treatment with vorasidenib. The primary endpoint is objective response rate by blinded independent central review, with additional evaluation of tumor growth rate and other efficacy outcomes.
Addressing Emerging Treatment Gaps
Nuvation Bio Founder, President, and Chief Executive Officer David Hung, M.D., said the longer-term findings strengthen confidence in safusidenib’s potential across multiple treatment settings for patients with IDH1-mutant glioma. He noted that the expanded clinical program aims to evaluate the therapy across a broader patient population and support development throughout the disease course.
Macarena de la Fuente, M.D., Chief of the Neuro-Oncology Division and Co-Director of Clinical Neuro-Oncology at the Sylvester Comprehensive Cancer Center, highlighted that treatment sequencing remains an important unanswered question as targeted therapies become more widely used. She said the new post-vorasidenib study addresses an important unmet clinical need for patients whose tumors progress after first-line targeted therapy.
Path Forawrd
The new studies complement the ongoing pivotal SIGMA (G203) Phase 3 trial (NCT05303519), which is evaluating safusidenib as maintenance therapy following standard treatment in patients with high-risk IDH1-mutant astrocytoma. SIGMA plans to enroll approximately 300 patients and also includes an exploratory cohort in grade 3 IDH1-mutant oligodendroglioma.
Together, the expanding development program positions safusidenib for evaluation across newly diagnosed, high-risk, and post-targeted therapy settings, potentially extending treatment options for patients with IDH1-mutant glioma where effective long-term disease control remains an unmet need.
Reference
About the Writer
Chikkula Pavan Kumar (LinkedIn), PharmD is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.